31 results about "Spin labeled" patented technology

A magnetic resonance imaging (MRI) method of obtaining MRI images of a patient and storing the images in physical storage media.

A magnetic resonance imaging (MRI) method of obtaining MRI images of a patient and storing the images in physical storage media.

Methods of producing and / or analyzing spectroscopically labeled proteins, e.g., proteins site-specifically labeled with NMR active isotopes, spin-labels, chelators for paramagnetic metals, and the like, are provided. The labeled proteins are produced in translation systems including orthogonal aminoacyl tRNA synthetase / tRNA pairs. Methods for assigning NMR resonances, e.g., methods using isotopically labeled proteins, are also provided.

Methods of producing and / or analyzing spectroscopically labeled proteins, e.g., proteins site-specifically labeled with NMR active isotopes, spin-labels, chelators for paramagnetic metals, and the like, are provided. The labeled proteins are produced in translation systems including orthogonal aminoacyl tRNA synthetase / tRNA pairs. Methods for assigning NMR resonances, e.g., methods using isotopically labeled proteins, are also provided.

The present invention relates to a kinase labelled at an amino acid naturally present or introduced in the P-loop of said kinase, wherein said labelling is effected at a free thiol or amino group of said amino acid and said label is (a) a thiol- or amino-reactive fluorophore sensitive to polarity changes in its environment; or (b) a thiol-reactive spin label, an isotope or an isotope-enriched thiol- or amino-reactive label, such that said fluorophore, spin label, isotope or isotope-enriched label does not inhibit the catalytic activity and does not interfere with the stability of the kinase. The invention furthermore relates to a method of screening for kinase inhibitors, a method of determining the kinetics of ligand binding and / or of dissociation of a kinase inhibitor and a method of generating mutated kinases suitable for the screening of kinase inhibitors using the kinase of the present invention.

The invention provides compositions and methods for assessing the capacity of high density lipoprotein (HDL) to support reverse cholesterol transport in blood by measuring exchange if HDL-specific spin-labeled lipoprotein probes and electron paramagnetic spectroscopy. The invention also provides methods to identify individuals at risk for cardiovascular disease, to monitor the treatment of cardiovascular disease and in the development of therapies to treat cardiovascular disease. The invention also provides methods to identify individuals at risk for Alzheimer's disease, to monitor the treatment of Alzheimer's disease and in the development of therapies to treat Alzheimer's disease.

The invention discloses a spin labeled fluorescent probe with single electron structure. The spin labeled fluorescent probe with single electron structure is prepared by the following method: (1) adding rhodamine B and 4-hydroxy-2, 2, 6, 6,-tetramethyl-piperidine nitrogen oxygen free radical into a reaction solvent dichloromethane, adding 4-dimethylaminopyridine to carry out reaction for 20min, then adding N, N'-dicyclohexyl carbodiimide, carrying out reaction at room temperature under argon protection for 24h; and (2) at the end of the reaction, removing the solvent, and subjecting the remaining materials to column chromatography separation: adopting dichloromethane / methanol=20 / 1 (v / v) as the eluant, taking 200-mesh neutral alumina as the stationary phase, collecting eluent, and removing the eluate. The spin labeled fluorescent probe with single electron structure provided by the invention has good cell permeability and low cytotoxicity, can be used for detection of intracellular hydroxyl radicals, mercapto free radicals and, cellular redox environment and oxidation resistance evaluation research of polyphenolic antioxidants.

Spin-labeled ice binding compounds (IBCs) including ice binding proteins (IBPs) or antifreeze proteins (AFPs) and their analogs may carry paramagnetic centers for dynamic nuclear polarization (DNP), for enhancing nuclear magnetic resonance (NMR) signal intensities. Use of spin-labeled IBCs to perform DNP exploits the IBCs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high DNP efficiency. Other advantages of using spin-labeled IBCs include cryo-protecting biological samples; cryo-preserving relative positions and orientations of the spin labeling groups; selecting positions and orientations of spin labeling groups with freedom and without technical barriers to making multiple spin labels in an IBC; and enabling use of a solvent that is primarily water for DNP at low temperatures in view of the potentially high water solubilities of spin-labeled IBCs.

The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.

Spin labeled ice binding compounds (IBCs) including ice binding proteins (IBPs), also called antifreeze proteins (AFPs) and their analogs are exploited to carry the paramagnetic centers for dynamic nuclear polarization (DNP), for enhancing nuclear magnetic resonance (NMR) signal intensities. Use of spin labeled IBCs to perform DNP exploits the IBCs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high DNP efficiency. Other advantages of using spin labeled IBCs include: (1) ability to cryo-protect biological samples; (2) the relative positions and orientations of the spin labeling groups in an IBC may also be cryo-preserved; (3) positions and orientations of spin labeling groups to an IBC can be selected with great freedom and without technical barrier to making multiple spin labels in an IBC; and (4) water solubilities of spin labeled IBCs are potentially high, enabling use of a solvent that is primarily water for DNP at low temperatures.

The invention discloses a spin-labeling luotonin A compound of formula (I) as shown in the specification, as well as a preparation method and application of the compound. In-vitro antitumor activity screening results show that compared with luotonin A, the spin-labeling luotonin A compound disclosed by the invention is relatively intense in inhibition activity on human lung adenocarcinoma cells (A549), human breast cancer cell lines (MDA-MB-468), human ovarian neoplasm cells (SKOV3) and human colon cancer cell lines (HCT 116), and has good application prospects.

The invention provides a longitudinal relaxation rate measurement system and a measurement method using the system. The system comprises a pump light unit, a confocal microscopic collection unit, a displacement unit, a microwave radiation unit, a static magnetic field unit, a diamond probe containing a nitrogen-vacancy color center and a computer control processing unit. The measurement method using the system comprises the following steps: S1, connecting a first biomolecule to hydrogel in a biochemical reaction manner; s2, cleaning the hydrogel after the operation in the step S1, dropwise adding second and third biomolecules with different spin labels onto the hydrogel for reaction, and then fully cleaning to obtain a to-be-detected sample of interaction of the first biomolecule, the second biomolecule and the third biomolecule; and S3, carrying out longitudinal relaxation rate measurement on the to-be-measured sample. The system can be used for measuring the interaction of biomolecules, and has the advantages of stable signal, high signal-to-noise ratio, capability of simultaneously detecting multi-channel biological samples and the like.

The invention discloses a magnetic resonance artery spin labeling cerebral perfusion imaging data artifact graph removal method. The method comprises steps that a structure image of a detected brain is acquired, the structure image is segmented to generate a grey matter probability graph GM and a white matter probability graph WM, the grey matter probability graph GM and the white matter probability graph WM form a reference image pmCBF, and artifact graphs of rheoencephalograms CBF1-CBFn at n time points of the detected brain are removed by utilizing the reference image pmCBF. The method is advantaged in that the artifact graphs of the rheoencephalogram sequence can be effectively removed, error reduction is realized, and image quality is improved.

A system and method is provided for magnetic resonance angiography (MRA) that includes applying a first labeling pulse sequence to a first labeling region having a first portion of a vasculature of a subject extending through the first labeling region to label spins moving within the first labeling region. A second labeling pulse sequence is applied to a second labeling region having a second portion of a vasculature of the subject extending through the second labeling region to label spins moving within the second labeling region. The first and second labeling pulse sequences include different labeling techniques. An imaging pulse sequence is applied to an imaging region having a third portion of a vasculature of the subject extending through the imaging region that is displaced from the first and second labeling region to acquire imaging data from the spins labeled by the first labeling pulse sequence and the second labeling pulse sequence. An MRA image is reconstructed of at least the third portion of the vasculature of the subject from the medical imaging data.

A method for site-specific modification of protein molecules includes providing a protein molecule having at least first and second non-terminal Cys residues at respective first and second sites within the protein molecule, providing a blocking molecule that is suitable to interact with the protein molecule to selectively block the second non-terminal Cys residue to prevent modifications of the second non-terminal Cys residue while leaving the first non-terminal Cys residue unblocked, and providing a Cys-modifying molecule that is suitable to modify the first non-terminal Cys residue. The blocking molecule according to an embodiment of the invention may be a protein molecule, DNA, an aptamer or synthetic organic molecules. The Cys-modifying molecule according to an embodiment of the invention may be a fluorophore, biotin, spin label, a sugar or a non-natural amino acid analogue.

Nitrone, nitroso, and nitroxide spintraps and spin labels and their reduction products are claimed for the treatment of dense breasts.